PreppinPeppers › Facts › Lab article
Foundayo gets an EMA green light, but what comes next
Agent view of https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next: the machine-readable facts of this Lab article. People see the full page at the same URL. Facts page: https://www.preppinpeppers.com/facts/foundayo-gets-an-ema-green-light-but-comes-next.
TL;DR
On 15 October 2026 EMA's medicines committee (the CHMP) recommended authorising Foundayo (orforglipron) for type 2 diabetes and weight management; the
Facts Index
| Fact ID | Category | Entity | Attribute | Value | Source |
|---|---|---|---|---|---|
| foundayo-gets-an-ema-green-light-but-comes-next:title | identity | Foundayo gets an EMA green light, but what comes next | title | Foundayo gets an EMA green light, but what comes next | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:published | identity | Foundayo gets an EMA green light, but what comes next | published | 2026-10-19 | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:author | identity | Foundayo gets an EMA green light, but what comes next | author | PreppinPeppers Editorial Team | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:topics | identity | Foundayo gets an EMA green light, but what comes next | topics | News, peptide news, research news | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:summary | content | Foundayo gets an EMA green light, but what comes next | summary | On 15 October 2026 EMA's medicines committee (the CHMP) recommended authorising Foundayo (orforglipron) for type 2 diabetes and weight management; the | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:section-1 | content | Foundayo gets an EMA green light, but what comes next | section | What did EMA's medicines committee recommend for Foundayo? | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:section-2 | content | Foundayo gets an EMA green light, but what comes next | section | What is confirmed, and what is still open? | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:section-3 | content | Foundayo gets an EMA green light, but what comes next | section | What does the published trial data show? | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:section-4 | content | Foundayo gets an EMA green light, but what comes next | section | What do people get wrong about this news, and what are the documented risks of untested product? | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:product-gansulin-metal-peptide-pen | products | Foundayo gets an EMA green light, but what comes next | references product | Gansulin Pen ยท Reusable Click-Dial, 3 ml (1-60 Units) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:product-gansulin-3ml-cartridge | products | Foundayo gets an EMA green light, but what comes next | references product | Gansulin-Compatible 3 ml Glass Cartridge for Pens (10-Pack) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:product-bacteriostatic-water-30ml | products | Foundayo gets an EMA green light, but what comes next | references product | Bacteriostatic Water 30 ml Multi-Dose Vial (Pfizer Hospira, USP) | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:source-pubmed-ncbi-nlm-nih-gov | source | Foundayo gets an EMA green light, but what comes next | cites | Liu et al., Am J Manag Care 2025: Navigating compounded semaglutide: what health care providers need to know - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:source-pubmed-ncbi-nlm-nih-gov-2 | source | Foundayo gets an EMA green light, but what comes next | cites | Wharton et al., N Engl J Med 2025: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:source-pubmed-ncbi-nlm-nih-gov-3 | source | Foundayo gets an EMA green light, but what comes next | cites | McCall et al., Expert Opin Drug Saf 2026: Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system - pubmed.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:source-pubchem-ncbi-nlm-nih-gov | source | Foundayo gets an EMA green light, but what comes next | cites | NCBI PubChem CID 137319706: Orforglipron (C48H48F2N10O5) - pubchem.ncbi.nlm.nih.gov | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:source-www-ema-europa-eu | source | Foundayo gets an EMA green light, but what comes next | cites | European Medicines Agency (EMA): Foundayo - medicine overview (CHMP opinion) (retrieved 2026-10-19) - www.ema.europa.eu | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
| foundayo-gets-an-ema-green-light-but-comes-next:source-www-ema-europa-eu-2 | source | Foundayo gets an EMA green light, but what comes next | cites | European Medicines Agency (EMA): New oral GLP-1 medicine for weight management and type 2 diabetes (retrieved 2026-10-19) - www.ema.europa.eu | Lab article (https://www.preppinpeppers.com/blogs/the-lab/foundayo-gets-an-ema-green-light-but-comes-next) (evidence) |
FAQ
- What did EMA recommend for Foundayo?
- EMA said the CHMP adopted a positive opinion on 15 October 2026, recommending a marketing authorisation for Foundayo (orforglipron) for type 2 diabetes and for weight management.
- Is Foundayo approved in the EU yet?
- EMA's overview says the summary of product characteristics will be published after the European Commission grants the marketing authorisation. The committee opinion is a recommendation, not the grant.
- What is orforglipron?
- EMA describes the active substance as a small, non-peptide molecule that activates the GLP-1 receptor. PubChem lists its formula as C48H48F2N10O5 and its molecular weight as 883.0.
- Who is the applicant for Foundayo?
- According to EMA's medicine overview, the applicant is Eli Lilly Nederland B.V.
- What side effects does EMA list for Foundayo?
- EMA's overview says the most common side effects are gastrointestinal, such as nausea, vomiting and diarrhoea.
- What did the phase 3 orforglipron trial examine?
- Wharton and colleagues (NEJM, 2025) ran a randomized, double-blind trial over 72 weeks in adults with obesity without diabetes. The primary end point was percent change in body weight from baseline.
- Do adverse-event reports show a product caused harm?
- No. A report records that an event was mentioned alongside a product. It does not prove the product caused the event.
- Is orforglipron a peptide?
- No. EMA calls it a small, non-peptide molecule, and the 2025 NEJM abstract describes it as nonpeptide.